Precision BioSciences rises as FDA fast-tracks gene therapy for muscle‑wasting disease

Precision Biosciences

09/03/2026 11:51

** Shares of drug developer Precision BioSciences DTIL.O rise 10% to $5.09 premarket

** Co says FDA granted Fast Track status to its experimental Duchenne therapy, PBGENE‑DMD

** DMD is a rare genetic disorder that causes progressive muscle weakening and loss, mostly in boys; PBGENE‑DMD aims to fix common genetic errors that cause the condition, co says

** Co says it plans to begin a mid‑stage trial in boys aged 2–7 to test safety and effectiveness

** U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs

** Shares rose ~9% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))